Tech Company Financing Transactions
Q Therapeutics Funding Round
Q Therapeutics, based in Salt Lake City, received $15 million in investment from Signal Peak Ventures, EPIC Ventures and Toucan Capital Corporation.
Transaction Overview
Company Name
Announced On
2/15/2008
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series B
Investors
Proceeds Purpose
Q is conducting preclinical studies to support the filing of an Investigational New Drug Application with the FDA using Q-Cells� (neural glial cells) for the treatment of transverse myelitis, a rapidly paralyzing subset of multiple sclerosis (MS). Clinical trials are anticipated at Johns Hopkins in 2009.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
417 Wakara Way 3510
Salt Lake City, UT 84108
USA
Salt Lake City, UT 84108
USA
Phone
Website
Email Address
Overview
The Company's first product, Q-Cells, is a cell-based therapeutic intended to replace the insulating myelin on damaged neurons as well as provide trophic support, thereby restoring or preserving normal function of neurons.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven Borst
VP - Bus. Development
Mahendra Rao
VP - R & D
James Campanelli
Browse more venture capital transactions:
Prev: 2/15/2008: Quintic venture capital transaction
Next: 2/15/2008: Nerites venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs